Godsey & Gibb Inc’s ALX Oncology ALXO Stock Holding History

Godsey & Gibb Inc’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-150	Closed	-$8K	–	96
2021 Q2	$8K	Buy	+150	New	+$8.98K	﹤0.01%	73

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Godsey & Gibb Inc's ALXO Position: Q3 2021 in Review

Godsey & Gibb Inc sold out of ALX Oncology (ALXO) in Q3 2021, closing a stake of 150 shares — an estimated $8K sold.

Godsey & Gibb Inc first reported a position in ALXO in Q2 2021 and held it in 1 quarter. The position peaked at $8K in Q2 2021. 114 funds tracked by Wall St. Rank hold ALXO as of Q3 2021.

Godsey & Gibb Inc reported no remaining ALX Oncology position as of Q3 2021 after selling out during the quarter.
Godsey & Gibb Inc sold 150 ALX Oncology shares in Q3 2021, an estimated $8K.
Godsey & Gibb Inc first reported a position in ALX Oncology in Q2 2021 and held it in 1 quarter.
Godsey & Gibb Inc's ALX Oncology position peaked at $8K in Q2 2021.
114 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2021.

Based on Godsey & Gibb Inc's 13F filing for Q3 2021, filed 12 Nov 2021.